A Phase I, Randomized, Single-Blind, Placebo Controlled Study to Assess the Safety, Tolerability and Pharmacodynamics Of AZD8601 After Single Dose Administration to Male Patients With Type II Diabetes Mellitus (T2DM)

Trial Profile

A Phase I, Randomized, Single-Blind, Placebo Controlled Study to Assess the Safety, Tolerability and Pharmacodynamics Of AZD8601 After Single Dose Administration to Male Patients With Type II Diabetes Mellitus (T2DM)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs AZD 8601 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; First in man
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Aug 2017 Planned End Date changed from 29 Dec 2017 to 2 Jan 2018.
    • 07 Aug 2017 Status changed from recruiting to active, no longer recruiting.
    • 13 Mar 2017 Planned End Date changed from 1 Jul 2017 to 29 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top